CALCR (calcitonin receptor) antibodies are tools used to study the calcitonin receptor, a class B G protein-coupled receptor (GPCR) encoded by the *CALCR* gene. This receptor binds calcitonin, a hormone involved in calcium homeostasis and bone metabolism, and its related peptides, such as amylin. CALCR is primarily expressed in osteoclasts, kidneys, and specific brain regions, playing roles in bone resorption, renal calcium excretion, and possibly neuroregulation. Dysregulation of CALCR signaling is linked to osteoporosis, Paget’s disease, and cancers like medullary thyroid carcinoma (MTC), where CALCR overexpression serves as a diagnostic marker.
CALCR antibodies are pivotal in research to detect receptor expression, localization, and function. Polyclonal and monoclonal variants enable applications such as immunohistochemistry, Western blotting, and flow cytometry. They help investigate CALCR's role in diseases and its interaction with ligands or downstream pathways. In cancer research, these antibodies aid in characterizing tumor phenotypes and evaluating therapeutic targets. Additionally, they support drug development by screening calcitonin analogs or antagonists for metabolic or oncologic therapies. Despite their utility, specificity and cross-reactivity with related GPCRs (e.g., AMY1 receptor) require validation. Overall, CALCR antibodies remain essential for unraveling the receptor’s pathophysiology and translational potential.